Elite in Multiple Myeloma

Dr. Guenther Koehne

Oncology | Hematology
Baptist Health Medical Group Oncology LLC
8900 N Kendall Dr, 
Miami, FL 
Accepting New Patients
Offers Telehealth
38 Years of Experience
Elite in Multiple Myeloma
Baptist Health Medical Group Oncology LLC
8900 N Kendall Dr, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Guenther Koehne is an Oncologist and a Hematologist in Miami, Florida. Dr. Koehne has been practicing medicine for over 38 years and is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Wilms Tumor, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Koehne is currently accepting new patients.

His clinical research consists of co-authoring 56 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 22 articles and participated in 3 clinical trials in the study of Multiple Myeloma.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Baptist Hospital Of Miami
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC
8900 N Kendall Dr, Miami, FL 33176

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Long-term Follow-up Study of Patients Who Received VOR33
A Long-term Follow-up Study of Patients Who Received VOR33
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Genetic
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Biological, Drug
Study Drugs: VOR33, Mylotarg
Study Phase: Phase 1/Phase 2
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Busulfan, Melphalan, Fludarabine
Study Phase: Phase 1
A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: WT1 Analog Peptide Vaccine, Sargramostim (GM-CSF), Lenalidomide
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19
Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Other, Biological
Study Drug: Umbilical cord lining stem cells
Study Phase: Phase 1/Phase 2
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid Malignancies
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-compatible Related or Unrelated Donors in Patients With B-Cell Lymphoid Malignancies
Enrollment Status: Withdrawn
Publish Date: November 01, 2023
Intervention Type: Biological
Study Drugs: Hematopoietic Stem Cells from HLA-Compatible Related, Hematopoietic Stem Cells from HLA Unrelated
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies
Enrollment Status: Withdrawn
Publish Date: September 27, 2022
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

56 Total Publications

Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Journal: HemaSphere
Published: March 26, 2024
Similar Doctors
Damian J. Green
Elite in Multiple Myeloma
Dr. Damian J. Green
Oncology
Elite in Multiple Myeloma
Dr. Damian J. Green
Oncology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (10.7 miles away)
305-689-8648
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Damian Green is an Oncologist in Miami, Florida. Dr. Green is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Gastrostomy, and Tissue Biopsy. Dr. Green is currently accepting new patients.

Distinguished in Multiple Myeloma
Dr. Carl O. Landgren
Hematology Oncology | Hematology | Oncology
Distinguished in Multiple Myeloma
Dr. Carl O. Landgren
Hematology Oncology | Hematology | Oncology

University Of Miami

1400 Nw 14th St, University Of Miami Hospit, 
Miami, FL 
 (10.4 miles away)
305-585-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carl Landgren is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Landgren is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Bone Marrow Transplant. Dr. Landgren is currently accepting new patients.

Distinguished in Multiple Myeloma
Dr. Benjamin T. Diamond
Hematology Oncology | Hematology
Distinguished in Multiple Myeloma
Dr. Benjamin T. Diamond
Hematology Oncology | Hematology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (10.7 miles away)
305-689-8648
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Diamond is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Diamond is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Relapsed Refractory Multiple Myeloma (RRMM). Dr. Diamond is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koehne's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile